Form 8-K

8-K — GLAUKOS Corp

Accession: 0001193125-26-323729

Filed: 2026-07-29

Period: 2026-07-29

CIK: 0001192448

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — gkos-20260729.htm (Primary)

EX-99.1 (gkos-ex99_1.htm)

EX-99.2 (gkos-ex99_2.htm)

GRAPHIC (img153405085_0.gif)

GRAPHIC (img154328606_0.gif)

GRAPHIC (img154328606_1.jpg)

GRAPHIC (img154328606_2.gif)

GRAPHIC (img154328606_3.gif)

GRAPHIC (img154328606_4.gif)

GRAPHIC (img154328606_5.jpg)

GRAPHIC (img154328606_6.jpg)

GRAPHIC (img154328606_7.jpg)

GRAPHIC (img154328606_8.jpg)

GRAPHIC (img154328606_9.jpg)

GRAPHIC (img154328606_10.gif)

GRAPHIC (img154328606_11.jpg)

GRAPHIC (img154328606_12.jpg)

GRAPHIC (img154328606_13.jpg)

GRAPHIC (img154328606_14.jpg)

GRAPHIC (img154328606_15.jpg)

GRAPHIC (img154328606_16.jpg)

GRAPHIC (img154328606_17.jpg)

GRAPHIC (img154328606_18.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: gkos-20260729.htm · Sequence: 1

8-K

false000119244800011924482026-07-292026-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2026

Glaukos Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-37463

33-0945406

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1 Glaukos Way

Aliso Viejo, California

92656

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 367-9600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock

GKOS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On July 29, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

A Quarterly Summary containing supplemental business and financial information for the Company’s second quarter ended June 30, 2026 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Quarterly Summary is also available in the “Financials & Filings” section of the Company’s investor relations website at https://investors.glaukos.com.

The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release of Glaukos Corporation, dated July 29, 2026

99.2

Quarterly Summary of Glaukos Corporation for the second quarter ended June 30, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLAUKOS CORPORATION

(Registrant)

By:

/s/ Alex R. Thurman

Name:

Alex R. Thurman

Title:

Senior Vice President & Chief Financial Officer

Date: July 29, 2026

EX-99.1

Filename: gkos-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

clewis@glaukos.com

Glaukos Announces Second Quarter 2026 Financial Results

Aliso Viejo, CA – July 29, 2026 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include:

•

Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis.

•

Glaucoma record net sales of $155.2 million in Q2 2026 increased 50% year-over-year.

•

U.S. Glaucoma record net sales of $118.5 million in Q2 2026 increased 64% year-over-year.

•

Gross margin of approximately 82% and non-GAAP gross margin of approximately 85% in Q2 2026.

•

Raised 2026 net sales guidance to $680 million to $700 million, compared to $620 million to $635 million previously.

“Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”

Second Quarter 2026 Financial Results

Net sales in the second quarter of 2026 of $185.6 million increased 50% on a reported basis, or 49% on a constant currency basis, compared to $124.1 million in the same period in 2025.

Gross margin for the second quarter of 2026 was approximately 82%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the second quarter of 2026 was approximately 85%, compared to approximately 83% in the same period in 2025.

Selling, general and administrative (SG&A) expenses for the second quarter of 2026 increased 39% to $116.1 million, compared to $83.4 million in the same period in 2025. Non-GAAP SG&A expenses for the second quarter of 2026 increased 34% to $111.7 million, compared to $83.1 million in the same period in 2025.

GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2026 increased 40% to $51.3 million, compared to $36.5 million in the same period in 2025.

Loss from operations in the second quarter of 2026 was $17.3 million, compared to operating loss of $22.7 million in the second quarter of 2025. Non-GAAP loss from operations in the second quarter of 2026 was $7.6 million, compared to non-GAAP operating loss of $16.6 million in the second quarter of 2025.

Net loss in the second quarter of 2026 was $18.4 million, or ($0.31) per diluted share, compared to net loss of $19.7 million, or ($0.34) per diluted share, in the second quarter of 2025. Non-GAAP net loss in the second

quarter of 2026 was $8.3 million, or ($0.14) per diluted share, compared to non-GAAP net loss of $13.6 million, or ($0.24) per diluted share, in the second quarter of 2025.

Included in non-GAAP loss from operations, non-GAAP net loss, and non-GAAP EPS for the second quarter of 2026 is an acquired in-process R&D (IPR&D) charge of $1.5 million, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.02) in the second quarter of 2026.

The company ended the second quarter of 2026 with approximately $289.3 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.

2026 Revenue Guidance

The company expects 2026 net sales to be in the range of $680 million to $700 million based on the latest foreign currency exchange rates.

Webcast & Conference Call

The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international) and enter Conference ID 626961391. A replay of the webcast will be archived on the company’s website following completion of the call.

Quarterly Summary Document

The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Forward-Looking Statements

or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; risks related to our capped call transactions; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on April 30, 2026, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which we expect to file on or before August 10, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Statement Regarding Use of Non-GAAP Financial Measures

incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Net sales

185,610

124,120

336,181

230,784

Cost of sales

34,016

26,896

67,355

51,212

Gross profit

151,594

97,224

268,826

179,572

Operating expenses:

Selling, general and administrative

116,060

83,375

209,003

154,048

Research and development

51,301

36,538

95,446

68,891

Acquired in-process research and development

1,500

Total operating expenses

168,861

119,913

305,949

222,939

Loss from operations

(17,267

)

(22,689

)

(37,123

)

(43,367

)

Non-operating income (expense):

Interest income

2,279

2,574

4,710

5,650

Interest expense

(1,459

)

(1,151

)

(2,584

)

(2,314

)

Other (expense) income, net

(1,274

)

1,857

(2,023

)

2,802

Total non-operating (expense) income

(454

)

3,280

103

6,138

Loss before taxes

(17,721

)

(19,409

)

(37,020

)

(37,229

)

Income tax provision

656

248

1,140

574

Net loss

(18,377

)

(19,657

)

(38,160

)

(37,803

)

Basic and diluted net loss per share

(0.31

)

(0.34

)

(0.65

)

(0.66

)

Weighted-average shares outstanding used to

compute basic and diluted net loss per share

58,818

57,205

58,419

56,922

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

June 30,

December 31,

2026

2025

(unaudited)

Assets

Current assets:

Cash and cash equivalents

114,485

90,813

Short-term investments

171,741

187,947

Accounts receivable, net

138,900

108,608

Inventory

59,306

63,564

Prepaid expenses and other current assets

31,346

24,052

Total current assets

515,778

474,984

Restricted cash

3,115

3,834

Property and equipment, net

112,114

113,253

Operating lease right-of-use asset

31,271

31,527

Finance lease right-of-use asset

38,197

39,404

Intangible assets, net

127,151

141,916

Goodwill

66,710

Deposits and other assets

26,185

21,859

Total assets

920,521

893,487

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

19,139

24,624

Accrued liabilities

83,190

76,651

Total current liabilities

102,329

101,275

Operating lease liability

35,491

35,767

Finance lease liability

67,345

68,109

Deferred tax liability, net

441

Other liabilities

32,429

31,740

Total liabilities

238,035

237,332

Stockholders' equity:

Preferred stock, $0.001 par value; 5,000 shares authorized; no

shares issued and outstanding as of June 30, 2026 and

December 31, 2025

Common stock, $0.001 par value; 150,000 shares authorized; 58,886

and 57,539 shares issued and 58,858 and 57,511 shares

outstanding at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital

1,651,465

1,586,056

Accumulated other comprehensive income

2,384

3,303

Accumulated deficit

(971,290

)

(933,130

)

Less treasury stock (28 shares as of June 30, 2026 and December 31,

2025)

(132

)

(132

)

Total stockholders' equity

682,486

656,155

Total liabilities and stockholders' equity

920,521

893,487

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

Q2 2026

Q2 2025

GAAP

Adjustments

Non-GAAP

GAAP

Adjustments

Non-GAAP

Cost of sales

34,016

(5,274

)

(a)(b)

28,742

26,896

(5,764

)

(a)(b)

21,132

Gross Margin

81.7

2.8

84.5

78.3

4.7

83.0

Operating expenses:

Selling, general and administrative

116,060

(4,404

)

(c)(d)(e)

111,656

83,375

(295

)

(f)

83,080

Loss from operations

(17,267

)

9,678

(7,589

)

(22,689

)

6,059

(16,630

)

Non-operating income (expense):

Interest expense

(1,459

)

369

(g)

(1,090

)

(1,151

)

(1,151

)

Net loss

(18,377

)

10,047

(h)

(8,330

)

(19,657

)

6,059

(h)

(13,598

)

Basic and diluted net loss per share

(0.31

)

0.17

(0.14

)

(0.34

)

0.10

(0.24

)

(a)

Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $4.8 million in Q2 2026 and $5.5 million in Q2 2025.

(b)

Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million in Q2 2026 and $0.2 million in Q2 2025.

(c)

Expenses of $3.3 million related to the Company’s trade secrets litigation and other litigation matters.

(d)

Expenses of $0.4 million associated with the integration of a major system.

(e)

Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(f)

Mobius acquisition-related transaction expense.

(g)

Interest expense related to the untimely payment of prior period payroll withholdings.

(h)

Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

Year-to-Date Q2 2026

Year-to-Date Q2 2025

GAAP

Adjustments

Non-GAAP

GAAP

Adjustments

Non-GAAP

Cost of sales

67,355

(13,949

)

(a)(b)

53,406

51,212

(11,287

)

(a)(b)

39,925

Gross Margin

80.0

4.1

84.1

77.8

4.9

82.7

Operating expenses:

Selling, general and administrative

209,003

(5,097

)

(c)(d)(e)

203,906

154,048

(295

)

(f)

153,753

Loss from operations

(37,123

)

19,046

(18,077

)

(43,367

)

11,582

(31,785

)

Non-operating income (expense):

Interest expense

(2,584

)

369

(g)

(2,215

)

(2,314

)

(2,314

)

Net loss

(38,160

)

19,415

(h)

(18,745

)

(37,803

)

11,582

(h)

(26,221

)

Basic and diluted net loss per share

(0.65

)

0.33

(0.32

)

(0.66

)

0.20

(0.46

)

(a)

Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $13.0 million year-to-date Q2 2026 and $11.0 million year-to-date Q2 2025.

(b)

Mobius acquisition-related amortization expense of developed intellectual property and distribution rights of $1.0 million year-to-date Q2 2026 and $0.2 million year-to-date Q2 2025.

(c)

Expenses of $4.0 million related to the Company’s trade secrets litigation and other litigation matters.

(d)

Expenses of $0.4 million associated with the integration of a major system.

(e)

Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(f)

Mobius acquisition-related transaction expense.

(g)

Interest expense related to the untimely payment of prior period payroll withholdings.

(h)

Reported Sales vs. Prior Periods (in thousands)

Year-over-Year Percent Change

Quarter-over-Quarter Percent Change

2Q 2026

2Q 2025

1Q 2026

Reported

Operations (1)

Currency (2)

Reported

Operations (1)

Currency (2)

International Glaucoma

36,631

31,251

35,808

17.2

16.4

0.8

2.3

2.6

(0.3

Total Net Sales

185,610

124,120

150,571

49.5

49.3

0.2

23.3

0.0

(1)

Operational growth excludes the effect of translational currency

(2)

Calculated by converting the current period numbers using the prior period’s average foreign exchange rates

EX-99.2

Filename: gkos-ex99_2.htm · Sequence: 3

EX-99.2

Exhibit 99.2

JULY 29, 2026

GLAUKOS CORPORATION (NYSE: GKOS)

SECOND QUARTER 2026 IN REVIEW

Important Information

This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.

Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP Financial Measures” in the “Additional Information” section of this document.

Conference Call Information

Date:

July 29, 2026

Time:

4:30 p.m. ET / 1:30 p.m. PT

Dial-in numbers:

1-833-461-5787 (U.S.), 1-585-542-9983 (International)

Confirmation ID:

626961391

Live webcast:

Events page at the Glaukos Investor Relations website at http://investors.glaukos.com or at this link.

Webcast replay:

A replay of the webcast will be archived on the Glaukos Investor Relations website following completion of the call.

JULY 29, 2026

SECOND QUARTER 2026 FINANCIAL RESULTS SUMMARY

Business Description

Ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel, dropless platform therapies designed to disrupt the conventional standard of care and improve outcomes for patients suffering from chronic eye diseases

Disease Categories

Glaucoma

Corneal Health

Retinal Disease

Revenue (Growth)

2Q 2026

$185.6 million

(+50% reported and +49% constant currency versus 2Q 2025)

Gross Margin (Non-GAAP)

2Q 2026

~85%

(versus ~83% in 2Q 2025)

Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash

$289.3 million as of June 30, 2026 (versus $280.5 million as of March 31, 2026)

FY2026 Sales Guidance

FY 2026 global consolidated revenues of $680 - $700 million expected

See “Statement Regarding Use of Non-GAAP Financial Measures” and the Non-GAAP reconciliations included within the Additional Information section of this document. Reconciliations for each of constant currency revenue growth, Non-GAAP Gross Margin, and the other non-GAAP financial measures disclosed in this document to the most directly comparable GAAP financial measure are provided.

JULY 29, 2026

Revenue Performance & Commercial Overview

Global Consolidated Revenue Performance

Glaukos reported record second quarter net revenues of $185.6 million that were up 50% on a reported basis, or 49% on a constant currency basis, versus 2Q 2025. Our second quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as early contributions of Epioxa®.

Franchise Revenue Performance

JULY 29, 2026

U.S. Glaucoma

Our record second quarter U.S. Glaucoma net revenues were approximately $118.5 million, representing year-over-year growth of 64% versus 2Q 2025 driven by growing contributions from iDose TR, which generated sales of approximately $74 million in the second quarter.

During the second quarter, we successfully advanced execution of our commercialization of iDose TR, a first-of-its-kind intracameral procedural pharmaceutical that was designed to continuously deliver glaucoma drug therapy for up to three years. Most importantly, iDose TR continues to deliver strong clinical outcomes that meaningfully improve patients’ lives, resulting in strong physician interest and adoption while helping to accelerate a broader treatment paradigm shift toward earlier, interventional glaucoma care.

International Glaucoma

Our record second quarter International Glaucoma net revenues were approximately $36.6 million, representing year-over-year growth of 17% on a reported basis, or 16% on a constant currency basis, versus 2Q 2025. The strong growth internationally during the second quarter was broad-based as we continue to scale our international infrastructure and increasingly drive MIGS forward as the standard of care in each region and major market in the world.

We remain in the early stages of expanding our IG and product portfolio initiatives globally ahead of anticipated new product approvals and expanding market access in the years to come.

Corneal Health

Our record second quarter Corneal Health net revenues were approximately $30.4 million, representing year-over-year growth of 48% versus 2Q 2025, including Epioxa net sales of approximately $11 million.

During the second quarter, we advanced our initial commercial launch plans for Epioxa, our novel, groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. We believe Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to reduce the pain associated with removal of the epithelium, streamline the procedure, and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers, and the healthcare system.

As the first and only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, Epioxa has been met with strong interest from surgeons and the broader ophthalmic community, reinforcing our confidence in its potential to redefine the treatment paradigm for this rare, sight-threatening disease.

We will continue to focus on expanding access for keratoconus patients suffering from this rarely diagnosed disease.

JULY 29, 2026

Additional Commercial Updates & Commentary

We have had several additional positive commercial updates worth highlighting here:

 Advanced commercial launch activities in the U.S. for iDose TR

o Growing number of trained surgeons and accounts

o Increasing utilization by the installed active surgeon base

o Broadening and streamlining market access among MACs, commercial, and Medicare Advantage payers

o Expanded set of peer-reviewed literature, now consisting of 24 different peer-reviewed publications highlighting iDose TR as a transformative new treatment alternative for patients suffering with glaucoma and ocular hypertension

o Accelerating marketing investments to support increased patient awareness and education

 Advanced initial commercial launch plans for Epioxa

o Epioxa commercial availability announced March 19, 2026

o Successfully established, and continue to selectively expand, a broad-reaching site-of-care network, with acquired O2N systems already actively deployed at locations covering roughly 85% of the U.S. population, and a broader pipeline of systems moving through approval processes that would expand our treatment reach to approximately 95%

o Market access:

 Advancing efforts with payors to secure access pathways or policy coverage for Epioxa, with access pathways now established for more than 125 million covered commercial lives in the U.S., including with the 5 largest payors, reflecting encouraging initial receptivity of Epioxa’s clinical value

 Product-specific J-code for Epioxa, J2789, became effective on July 1, 2026, and is expected to help streamline the reporting and reimbursement process for Epioxa among U.S. payors over time

o Deployed various new patient services and support programs

o Advancing targeted marketing and DTC campaigns designed to significantly enhance awareness, education, and detection, supported by greater optometric engagement and strengthened advocacy partnerships

o Expanded new financial co-pay assistance program and operationalized Specialty Pharmacy partner network in support of Epioxa patients

JULY 29, 2026

 CMS’s Proposed Rules for Calendar Year 2027

o Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Facility Fee Schedules: Proposed to maintain the 2026 APC assignments and largely maintain facility fee rates associated with our procedures across both the hospital outpatient and ASC settings.

o Physician Fee Schedule (PFS) updates: Proposed modest reductions in physician fee reimbursement for several Category 1 CPT codes across ophthalmology, including for cataract and surgical MIGS procedures specifically.

JULY 29, 2026

2026 Revenue Guidance Raised to Reflect Strong Momentum

Glaukos now expects full-year 2026 global consolidated net sales of $680 - $700 million, up from its previous guidance of $620 - $635 million. This guidance attempts to take into consideration:

 Potential growing contributions from iDose TR as market access initiatives progress and broader IG initiatives take hold over the course of the year

 Potential growing contributions from Epioxa as commercial launch plans advance and permanent J-code is effective and solidified operationally

 Potential transient headwinds within our U.S. Corneal Health franchise during the third quarter associated with the Photrexa to Epioxa transition and ongoing operationalization of Epioxa’s now effective J-code

 Potential growing contributions from iStent infinite as broader IG initiatives take hold

 Uncertainties associated with five MAC’s proposed LCDs for iDose TR

 Combo-cataract MIGS competition globally

 The continued estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery versus other more invasive alternatives

 The latest foreign currency exchange spot rates as of our 2Q 2026 earnings call on July 29, 2026

 Global macroeconomic and geopolitical environment and associated uncertainties, which at this time are difficult to predict

JULY 29, 2026

Research & Development / Pipeline Overview

Pipeline Summary

Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows:

 iStent® micro-scale surgical devices

 iDose® sustained-release procedural pharmaceuticals

 iLink® bio-activated pharmaceuticals

 iLution™ transdermal pharmaceuticals

 Retina XR bio-erodible sustained-release pharmaceuticals

JULY 29, 2026

Key R&D and Pipeline Updates

We are continuing to invest in and advance our fulsome pipeline of core novel platforms, supported by more than $900 million investment into R&D since 2018 alone. Recent updates in our pipeline include:

iDose Platform Updates

 Announced U.S. FDA approval for NDA labeling supplement allowing for unlimited re-administration of iDose TR in patients who maintain a healthy cornea (January 2026)

 Advancing Phase 2b/3 clinical program for iDose TREX, our next-generation iDose therapy

o Initial results of Phase 2a clinical trial demonstrated substantial IOP reductions of 8.6 to 10.8 mmHg through 3 months

 Completed patient enrollment in Phase 3b study for iDose TRIO

o Initial human factors study indicated strong user preference (~90% favorability)

 Advancing various Phase 4 studies for iDose TR, including recently completed patient enrollment in Phase 4 study evaluating iDose TR + cataract surgery versus cataract surgery alone

iLink Platform Updates

 Announced U.S. FDA approval for Epioxa (Epi-on) (October 2025)

o Epioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated

o Epioxa ushers in a new standard of care for patients

 Advancing development of KC screening device to support planned commercialization in 2H 2026

 Preparing to commence Phase 3 clinical program for third-generation, customized, topography-guided iLink therapy in 2027

 Advancing Phase 2 clinical trial for iVeena

JULY 29, 2026

iStent Platform Updates

 Completed patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients (4Q 2025)

 Announced EU MDR certification for iStent infinite (June 2025)

 Completed patient enrollment in 510(k) pivotal study for PRESERFLO™ MicroShunt (July 2026)

iLution Platform Updates

 Completed enrollment in Phase 2 clinical trial for iLution™ Blepharitis (2Q 2026)

Retina XR Platform Updates

 Completed patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401) (4Q 2025)

JULY 29, 2026

Product / Pipeline Chart

JULY 29, 2026

Other Financial Performance Overview

As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section contained herein, as well as the Investor Relations section of our website.

Second quarter 2026 financial performance summary:

2Q 2026: 85%

2Q 2025: 83%

YoY ∆: +150 bps

 Please note that our non-GAAP adjustments to cost of goods sold include substantial amounts related to Avedro and Mobius acquisitions accounting

2Q 2026: $111.7M

2Q 2025: $83.1M

YoY ∆: +34%

 +21% sequential increase vs $92.2M in 1Q 2026

 YoY and QoQ increases primarily reflect commercial and G&A investments globally and new product launch activities, along with approximately $15M in one-time stock compensation expenses associated with the triggering of certain performance awards in 2Q 2026

2Q 2026: $51.3M

2Q 2025: $36.5M

YoY ∆: +40%

 +16% sequential increase vs $44.1M in 1Q 2026

 YoY and QoQ increases primarily reflect continued investment in and advancement of R&D programs and clinical trials

2Q 2026: $163.0M

2Q 2025: $119.6M

YoY ∆: +36%

 +19% sequential increase vs $136.4M in 1Q 2026

Op Loss (Non-GAAP)

2Q 2026 ($7.6M)

2Q 2025: ($16.6M)

Net Loss (Non-GAAP)

2Q 2026: ($8.3M)

2Q 2025: ($13.6M)

Diluted EPS (Non-GAAP)

2Q 2026: ($0.14)

2Q 2025: ($0.24)

 Included in non-GAAP loss from operations, non-GAAP net loss, and non-GAAP EPS for the second quarter of 2026 is an acquired in-process R&D (IPR&D) charge of $1.5 million, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.02)

2Q 2026: $2.7M

2Q 2025: $1.2M

YoY ∆: +$1.5M

 Capital expenditures reflect normal course spend primarily on business maintenance activities and equipment upgrades

2Q 2026: $289.3M

1Q 2026: $280.5M

QoQ ∆: +$8.8M

JULY 29, 2026

Other Important Updates

 Given the ongoing conversations around tariff and broader geopolitical volatility, we wanted to reiterate that we manufacture and source our products primarily within the U.S., and as such, expect minimal direct exposure to the most recently implemented tariff-related policies. That said, the global tariff environment remains fluid, and more broadly, the current geopolitical backdrop and macroeconomic uncertainties continue to evolve. As such, we will continue to closely monitor these situations given the overall instability in the marketplace and global macroeconomic uncertainties.

JULY 29, 2026

Additional Information

JULY 29, 2026

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR and Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; risks related to our capped call transactions; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the SEC on April 30, 2026, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which we expect to file on or before August 10, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof.

JULY 29, 2026

We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Statement Regarding Use of Non-GAAP Financial Measures

To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “Primary GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure. Beginning in the second quarter of 2022, we no longer exclude certain upfront and contingent milestone payments in connection with collaborative and licensing arrangements and certain in-process R&D charges for non-GAAP reporting and disclosure purposes.

In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Additional GAAP to Non-GAAP Reconciliations” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.

JULY 29, 2026

GAAP Income Statement

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Net sales

185,610

124,120

336,181

230,784

Cost of sales

34,016

26,896

67,355

51,212

Gross profit

151,594

97,224

268,826

179,572

Operating expenses:

Selling, general and administrative

116,060

83,375

209,003

154,048

Research and development

51,301

36,538

95,446

68,891

Acquired in-process research and development

1,500

Total operating expenses

168,861

119,913

305,949

222,939

Loss from operations

(17,267

)

(22,689

)

(37,123

)

(43,367

)

Non-operating income (expense):

Interest income

2,279

2,574

4,710

5,650

Interest expense

(1,459

)

(1,151

)

(2,584

)

(2,314

)

Other (expense) income, net

(1,274

)

1,857

(2,023

)

2,802

Total non-operating (expense) income

(454

)

3,280

103

6,138

Loss before taxes

(17,721

)

(19,409

)

(37,020

)

(37,229

)

Income tax provision

656

248

1,140

574

Net loss

(18,377

)

(19,657

)

(38,160

)

(37,803

)

Basic and diluted net loss per share

(0.31

)

(0.34

)

(0.65

)

(0.66

)

Weighted-average shares outstanding used to

compute basic and diluted net loss per share

58,818

57,205

58,419

56,922

JULY 29, 2026

GAAP Balance Sheet

GLAUKOS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par values)

June 30,

December 31,

2026

2025

(unaudited)

Assets

Current assets:

Cash and cash equivalents

114,485

90,813

Short-term investments

171,741

187,947

Accounts receivable, net

138,900

108,608

Inventory

59,306

63,564

Prepaid expenses and other current assets

31,346

24,052

Total current assets

515,778

474,984

Restricted cash

3,115

3,834

Property and equipment, net

112,114

113,253

Operating lease right-of-use asset

31,271

31,527

Finance lease right-of-use asset

38,197

39,404

Intangible assets, net

127,151

141,916

Goodwill

66,710

Deposits and other assets

26,185

21,859

Total assets

920,521

893,487

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

19,139

24,624

Accrued liabilities

83,190

76,651

Total current liabilities

102,329

101,275

Operating lease liability

35,491

35,767

Finance lease liability

67,345

68,109

Deferred tax liability, net

441

Other liabilities

32,429

31,740

Total liabilities

238,035

237,332

Stockholders' equity:

Preferred stock, $0.001 par value; 5,000 shares authorized; no shares

issued and outstanding as of March 31, 2026 and December 31, 2025

Common stock, $0.001 par value; 150,000 shares authorized; 58,387

and 57,539 shares issued and 58,359 and 57,511 shares outstanding

at March 31, 2026 and December 31, 2025, respectively

Additional paid-in capital

1,651,465

1,586,056

Accumulated other comprehensive income

2,384

3,303

Accumulated deficit

(971,290

)

(933,130

)

Less treasury stock (28 shares as of March 31, 2026 and December 31,

2025)

(132

)

(132

)

Total stockholders' equity

682,486

656,155

Total liabilities and stockholders' equity

920,521

893,487

JULY 29, 2026

Primary GAAP to Non-GAAP Reconciliations

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited)

Q2 2026

Q2 2025

GAAP

Adjustments

Non-GAAP

GAAP

Adjustments

Non-GAAP

Cost of sales

34,016

(5,227

)

(a)(b)

28,742

26,896

(5,764

)

(a)(b)

21,132

Gross Margin

81.7

2.8

84.5

78.3

4.7

83.0

Operating expenses:

Selling, general and administrative

116,060

(4,404

)

(c)(d)(e)

111,656

83,375

(295

)

(f)

83,080

Loss from operations

(17,267

)

9,678

(7,589

)

(22,689

)

6,059

(16,630

)

Non-operating income (expense):

Interest expense

(1,459

)

369

(g)

(1,090

)

(1,151

)

(1,151

)

Net loss

(18,377

)

10,047

(h)

(8,330

)

(19,657

)

6,059

(h)

(13,598

)

Basic and diluted net loss per

(0.31

)

0.17

(0.14

)

(0.34

)

0.10

0.24

(a)

(b)

Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million in Q2 2026 and $0.2 million in Q2 2025.

(c)

Expenses of $3.3 million related to the Company’s trade secrets litigation and other litigation matters.

(d)

Expenses of $0.4 million associated with the integration of a major system.

(e)

Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(f)

Mobius acquisition-related transaction expense.

(g)

Interest expense related to the untimely payment of prior period payroll withholdings.

(h)

JULY 29, 2026

Primary GAAP to Non-GAAP Reconciliations

GLAUKOS CORPORATION

GAAP to Non-GAAP Reconciliations

(in thousands, except per share amounts and percentage data)

(unaudited

Year-to-Date Q2 2026

Year-to-Date Q2 2025

GAAP

Adjustments

Non-GAAP

GAAP

Adjustments

Non-GAAP

Cost of sales

67,355

(13,949

)

(a)(b)

53,406

51,212

(11,287

)

(a)(b)

39,925

Gross Margin

80.0

4.1

84.1

77.8

4.9

82.7

Operating expenses:

Selling, general and administrative

209,003

(5,097

)

(c)(d)(e)

203,906

154,048

(295

)

(f)

153,753

Loss from operations

(37,123

)

19,046

(18,077

)

(43,367

)

11,582

(31,785

)

Non-operating income (expense):

Interest expense

(10,128

)

3,324

(c)

(6,804

)

(10,128

)

3,324

(c)

(6,804

)

Interest expense

(2,584

)

369

(g)

(2,215

)

(2,314

)

(2,314

)

Net loss

(38,160

)

19,415

(h)

(18,745

)

(37,803

)

11,582

(h)

(26,221

)

Basic and diluted net loss per

(0.65

)

(0.33

)

(0.32

)

(0.66

)

0.20

(0.46

)

(a)

(b)

Mobius acquisition-related amortization expense of developed intellectual property and distribution rights of $1.0 million year-to-date Q2 2026 and $0.2 million year-to-date Q2 2025.

(c)

Expenses of $4.0 million related to the Company’s trade secrets litigation and other litigation matters.

(d)

Expenses of $0.4 million associated with the integration of a major system.

(e)

Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million.

(f)

Mobius acquisition-related transaction expense.

(g)

Interest expense related to the untimely payment of prior period payroll withholdings.

(h)

JULY 29, 2026

Additional GAAP to Non-GAAP Reconciliations

Reported Sales vs. Prior Periods (in thousands)

Year-over-Year Percent Change

Quarter-over-Quarter Percent Change

1Q 2026

1Q 2025

4Q 2025

Reported

Operations (1)

Currency (2)

Reported

Operations (1)

Currency (2)

International

Glaucoma

36,631

31,251

35,808

17.2

16.4

0.8

2.3

2.6

(0.3

Total Net Sales

185,610

124,120

150,571

49.5

49.3

0.2

23.3

0.0

(1)

Operational growth excludes the effect of translational currency

(2)

Calculated by converting the current period numbers using the prior period’s average foreign exchange rates

For Non-GAAP disclosures associated with the company’s past quarterly results, included with respect to the sequential comparisons included herein, please see reconciliations here.

GRAPHIC

Filename: img153405085_0.gif · Sequence: 4

Binary file (31934 bytes)

Download img153405085_0.gif

GRAPHIC

Filename: img154328606_0.gif · Sequence: 5

Binary file (31934 bytes)

Download img154328606_0.gif

GRAPHIC

Filename: img154328606_1.jpg · Sequence: 6

Binary file (70603 bytes)

Download img154328606_1.jpg

GRAPHIC

Filename: img154328606_2.gif · Sequence: 7

Binary file (20049 bytes)

Download img154328606_2.gif

GRAPHIC

Filename: img154328606_3.gif · Sequence: 8

Binary file (26797 bytes)

Download img154328606_3.gif

GRAPHIC

Filename: img154328606_4.gif · Sequence: 9

Binary file (71165 bytes)

Download img154328606_4.gif

GRAPHIC

Filename: img154328606_5.jpg · Sequence: 10

Binary file (10150 bytes)

Download img154328606_5.jpg

GRAPHIC

Filename: img154328606_6.jpg · Sequence: 11

Binary file (10047 bytes)

Download img154328606_6.jpg

GRAPHIC

Filename: img154328606_7.jpg · Sequence: 12

Binary file (9664 bytes)

Download img154328606_7.jpg

GRAPHIC

Filename: img154328606_8.jpg · Sequence: 13

Binary file (10221 bytes)

Download img154328606_8.jpg

GRAPHIC

Filename: img154328606_9.jpg · Sequence: 14

Binary file (10613 bytes)

Download img154328606_9.jpg

GRAPHIC

Filename: img154328606_10.gif · Sequence: 15

Binary file (84971 bytes)

Download img154328606_10.gif

GRAPHIC

Filename: img154328606_11.jpg · Sequence: 16

Binary file (7362 bytes)

Download img154328606_11.jpg

GRAPHIC

Filename: img154328606_12.jpg · Sequence: 17

Binary file (6121 bytes)

Download img154328606_12.jpg

GRAPHIC

Filename: img154328606_13.jpg · Sequence: 18

Binary file (5882 bytes)

Download img154328606_13.jpg

GRAPHIC

Filename: img154328606_14.jpg · Sequence: 19

Binary file (6975 bytes)

Download img154328606_14.jpg

GRAPHIC

Filename: img154328606_15.jpg · Sequence: 20

Binary file (4844 bytes)

Download img154328606_15.jpg

GRAPHIC

Filename: img154328606_16.jpg · Sequence: 21

Binary file (4125 bytes)

Download img154328606_16.jpg

GRAPHIC

Filename: img154328606_17.jpg · Sequence: 22

Binary file (4211 bytes)

Download img154328606_17.jpg

GRAPHIC

Filename: img154328606_18.jpg · Sequence: 23

Binary file (51686 bytes)

Download img154328606_18.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 26

v3.26.1

Document And Entity Information

Jul. 29, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 29, 2026

Entity Registrant Name

Glaukos Corporation

Entity Central Index Key

0001192448

Entity Emerging Growth Company

false

Entity File Number

001-37463

Entity Incorporation, State or Country Code

Entity Tax Identification Number

33-0945406

Entity Address, Address Line One

1 Glaukos Way

Entity Address, City or Town

Aliso Viejo

Entity Address, State or Province

Entity Address, Postal Zip Code

92656

City Area Code

(949)

Local Phone Number

367-9600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

GKOS

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration